TransitionConsulting
RESEARCH INTELLIGENCE
Professional information research, analysis, and visualization — sourced from trusted, verifiable literature (PubMed, Springer Nature, JAMA, NEJM, The Lancet, WHO) and delivered as an interactive dashboard, not a pile of PDFs. Built for clinicians, researchers, and organizations who don't have the hours to do the searching, filtering, and reading themselves.
4
Live dashboards below
3
Medical specialties covered
778+
Publications analyzed across cases
100%
Sourced & linked, no black box
Literature Intelligence reads the published science. Signal Intelligence reads trial registries, deals, regulatory actions and patents, before they reach a journal.
A worked nephrology example — published literature paired with live clinical-trial-registry movement, every figure traced to a DOI or an NCT number. The same method runs behind every dashboard on this page.
Nephrology / CKD example — the same two-layer method applies to any specialty above.
This method produces two different products: the literature landscape becomes the Dashboards below; the live registry movement becomes Pipeline Radar.
Systematic, multi-pass searches across PubMed, Springer Nature, JAMA, NEJM, The Lancet, and regulatory/public-health sources — every citation checked against the source text before it's used.
Thematic clustering, study-design breakdowns, and a specialist-level read of what actually changed — not just a list of abstracts.
An interactive dashboard you can search, filter, and export — built so a busy professional gets the answer in minutes, not hours.
The first three are full-corpus landscape analyses built from hundreds of full-text articles indexed on Springer Nature platforms (BMC journals, Nature Portfolio, and specialty Springer titles). The fourth is a live example of our recurring monthly subscription product.
134 peer-reviewed publications across 56 journals — CKD/AKI biomarkers, RRT, SGLT2 inhibitors, and an interactive 48h renal-recovery predictor.
Open dashboard Pediatrics · N=346346 publications across 19 journals — neonatology, pain management, ADHD, and an interactive bilirubin-encephalopathy risk calculator.
Open dashboard Psychiatry · N=298298 publications across 39 journals — neuromodulation, digital mental health, global suicide burden, plus an AI research-assistant chat and DMN-response simulator.
Open dashboard Live product demo · Monthly subscriptionA sample issue of our recurring subscription: 62 independently search-verified sources from the last quarter, a full-report PDF export, and practice-relevant clinical snapshots. This is what lands in your inbox every month.
Open dashboardWe identify your field's most active research axes and set a recency window (typically the last 1–3 months).
Multi-pass search across trusted databases; every title, journal, date, and DOI is checked against the source before inclusion.
Thematic and study-design breakdowns, specialist-level narrative on what actually changed and why it matters.
A searchable, exportable, offline-readable brief — refreshed on your schedule.
By the time a pharma story reaches a journal or a press release, it's typically two to five years old. Trial registrations — and especially trial status changes — are the leading indicator: a company entering a space, a competitor's programme quietly failing, a suspension pending an acquisition. All of it is visible in the public clinical-trial registry before it reaches a publication.
An automated query against ClinicalTrials.gov for one condition at a time — no manual searching, no missed pages.
Five commercial categories: new entrants, stopped trials, late-stage starts, emerging interventions, sponsor momentum.
Every row carries its NCT number — one click to verify against the source record yourself.
The tool finds candidates; a specialist reviews every signal before it reaches a client. Judgment stays human.
Illustrative example — chronic kidney disease, live as of 2026-08-21
5,746
CKD trials scanned
1,858
Distinct sponsors
45
New industry entrants
74
Stopped in window
Alexion Pharmaceuticals · NCT05746559
Phase 3, terminated 2026-07-22. ARTEMIS — ravulizumab, 555 patients, discontinued for lack of efficacy. A late-stage, large-enrollment failure like this rarely reaches a publication for years, if at all.
Apellis Pharmaceuticals · NCT07020832
Phase 3, suspended 2026-06-18. Pegcetacoplan, 320 patients, for delayed graft function after kidney transplant — suspended pending a corporate acquisition and strategic review, an M&A signal visible in the registry well before any public announcement.
Specimen
A hand-picked highlight reel — the free door-opener.
Full report
Every signal category, top rows by significance — generated per condition.
Complete data
Every trial, no cap — .csv exports alongside the report.
Already mapped — any condition in the registry works
Honest limits
Absence of a trial isn't absence of a programme. Sponsor names aren't harmonized across corporate entities. Stop-reasons are self-reported and sometimes uninformative. Every signal is a candidate for specialist review — not a finished conclusion.
Add deals, regulatory actions and patents to the registry layer, with counter-signals and dated forecasts scored in public. Flagship case: in vivo CAR-T, three FDA clearances in six weeks.
Dashboards
A dashboard like the ones above, refreshed monthly for your specialty — Nephro-Pulse, Pedia-Pulse, Psych-Pulse, or a new one built for your field.
Monthly PDF brief + static dashboard, one sub-specialty.
Full interactive dashboard, searchable archive, CME-ready summary.
Department-wide access, custom sub-topics, quarterly live journal club, API export.
Project-based, deep-research method
Name a topic — a molecule, a guideline update, a competitive landscape — and get a verified 60–150-source dashboard plus written analysis, delivered in 48–72 hours.
Single topic, ~60–80 sources, 48–72h turnaround.
Multi-axis analysis, 100–150+ sources, presentation-ready.
Monthly refreshed watch-brief on your area of interest.
Pipeline Radar
Same combined two-layer pricing as our Deep-Dive Briefs — every Radar engagement includes the literature layer.
Single condition, combined literature + registry layers, 48–72h turnaround.
Multi-axis analysis, presentation-ready, both layers combined.
Scheduled re-run, delta-only reporting on what changed since last time.
Need all four layers? Signal Landscape from $4,000 · Signal Watch from $900/mo. See Signal Intelligence
Whether it's a monthly Pulse subscription for your specialty, a one-off deep-dive brief, or a Pipeline Radar scan — send a note and we'll scope it.
Site
research.transitionconsultings.com